Protein: MAP1LC3B
PDB ID: 8Q53
Deposition Date: Tuesday 8th August 2023
Authors: Kumar, A., Knapp, S.
Protein: JMJD1C
PDB ID: 9GDK
Deposition Date: Monday 5th August 2024
Authors: Fairhead, M., Strain-Damerell, C., Ye, M., Mackinnon, S.R., Pinkas, D., MacLean, E.M., Koekemoer, L., Damerell, D., Krojer, T., Arrowsmith, C.H., Edwards, A., Bountra, C., Yue, W., Burgess-Brown, N., Marsden, B., von Delft, F.
Protein: PHIP
PDB ID: 9GH3
Deposition Date: Wednesday 14th August 2024
Authors: Fairhead, M., Strain-Damerell, C., Ye, M., Mackinnon, S.R., Pinkas, D., MacLean, E.M., Koekemoer, L., Damerell, D., Krojer, T., Arrowsmith, C.H., Edwards, A., Yue, W., Burgess-Brown, N., Marsden, B., von Delft, F.
29.08.2024

From Structure to Function: Cbl-b Inhibition in Cancer Immunotherapy

by: SGC

The human immune system serves as our body’s defense against harmful pathogens and cancer by identifying and eliminating abnormal cells. To maintain immune homeostasis several mechanisms are employed, which involve a wide range of proteins, including the Casitas B lymphoma-b (Cbl-b) protein, present in various immune cells. Cbl-b helps modulate immune responses by downregulating the activity of multiple immune cells. This inhibitory effect is significant in cancer development and progression as it promotes an immunosuppressive tumor environment.

Protein: TRIP12
PDB ID: 9BKR
Deposition Date: Monday 29th April 2024
Authors: Kimani, S., Dong, A., Li, Y., Arrowsmith, C.H., Edwards, A.M., Halabelian, L.
Protein: TRIP12
PDB ID: 9BKS
Deposition Date: Monday 29th April 2024
Authors: Kimani, S., Dong, A., Li, Y., Arrowsmith, C.H., Edwards, A.M., Halabelian, L.